Literature DB >> 9519730

Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.

J Calles-Escandon1, S A Mirza, B E Sobel, D J Schneider.   

Abstract

Hypofibrinolysis caused by increased plasminogen activator inhibitor 1 (PAI-1) has been implicated in the vasculopathy of type 2 diabetes, typified by increased insulin, glucose, and triglycerides. However, short-term infusions of insulin have not increased PAI-1 in normal subjects. We hypothesized that induction of increased insulin accompanied by increased glucose and triglycerides would increase PAI-1. Accordingly, 30% glucose and 10% Intralipid were infused for 6 h in ten normal lean individuals (54 +/- 3 years) resulting in increased insulin (42 +/- 5 microU/dl), glucose (200 +/- 24 mg/dl), and triglycerides (425 +/- 45 mg/dl), simulating changes in type 2 diabetes. In contrast to results with infusion of saline alone (n = 16) and euglycemic-hyperinsulinemic clamps (n = 10, serum insulin = 89 +/- 7 microU/dl), PAI-1 in blood increased significantly 6 h after the onset of infusion (15 +/- 5 ng/ml, P < 0.05 vs. baseline = 7.4 +/- 1.1, saline 6 h = 3.4 +/- 1.1, and insulin alone 6 h = 3.7 +/- 0.8) and remained elevated for an additional 6 h (combined infusion = 13.8 +/- 3.8 ng/ml, saline = 6.7 +/- 2 ng/ml, insulin alone = 7.8 +/- 1.7 ng/ml, P = 0.06). Our data suggest that combined hyperinsulinemia, hypertriglyceridemia, and hyperglycemia are likely to contribute to hypofibrinolysis of type 2 diabetes by increasing the blood levels of PAI-1. Moreover, these results underscore the potential importance of modifying insulin resistance as well as achieving glycemic and lipidemic control in individuals with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519730     DOI: 10.2337/diab.47.2.290

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Percutaneous coronary intervention in diabetics.

Authors:  Juhana Karha; Deepak L Bhatt
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

3.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

4.  Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats.

Authors:  Y Mori; K Ojima; Y Fuujimori; Y Fujimori; I Aoyagi; H Kusama; Y Yamazaki; M Kojima; S Kojima; N Shibata; Y Itoh; N Tajima
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

5.  Inflammatory and metabolic markers and short-time outcome in patients with acute ischemic stroke in relation to TOAST subtypes.

Authors:  Marcio Francisco Lehmann; Ana Paula Kallaur; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Franciele Delongui; Johnathan de Sousa Parreira; Maria Caroline Martins de Araújo; Carolina Rossato; Jéssica Tavares de Almeida; Larissa Moliterno Pelegrino; Erick Frank Bragato; Ana Lucia Cruz Fürstenberger Lehmann; Helena Kaminami Morimoto; Marcell Alysson Batisti Lozovoy; Andrea Name Colado Simão; Damácio Ramon Kaimen-Maciel; Edna Maria Vissoci Reiche
Journal:  Metab Brain Dis       Date:  2015-09-11       Impact factor: 3.584

Review 6.  Insulin and the vasculature.

Authors:  N Mikhail; M L Tuck
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

Review 7.  Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus.

Authors:  Serdar Farhan; Thomas Höchtl; Alexandra Kautzky-Willer; Johann Wojta; Kurt Huber
Journal:  Wien Med Wochenschr       Date:  2010-01

Review 8.  Adipokines, inflammation, and the endothelium in diabetes.

Authors:  Waleed Aldhahi; Osama Hamdy
Journal:  Curr Diab Rep       Date:  2003-08       Impact factor: 4.810

Review 9.  Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.

Authors:  Mark W Gramling; Frank C Church
Journal:  Thromb Res       Date:  2010-01-15       Impact factor: 3.944

Review 10.  Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.

Authors:  Susanne Trost; Richard Pratley; Burton Sobel
Journal:  Curr Diab Rep       Date:  2006-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.